NEUROGEN CORP 424B2, filed Jan 13, 2004: r424b2.htm
To Prospectus dated February 13, 2003
1,783,252 SHARES
Neurogen Corporation
Common Stock
Par Value $0.025 per share
We are selling all of the 1,783,252 shares of common stock offered by this prospectus supplement to one investor. Our common stock is traded on the Nasdaq National Market under the symbol "NRGN". We will receive the proceeds from the sale of the shares. The last reported sale price of our common stock on the Nasdaq National Market on January 12, 2004 was $9.08 per share.
INVESTING IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. SEE "RISK FACTORS" BEGINNING ON PAGE S-4 OF THIS PROSPECTUS SUPPLEMENT AND PAGE 3 OF THE ACCOMPANYING PROSPECTUS.
Per Share |
Total |
|
| Offering Price .......................................................................................................................... | $8.4116 |
$15,000,003 |
We expect that delivery of the shares of common stock offered by this prospectus supplement will be made on or about January 13, 2004.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS SUPPLEMENT OR THE ACCOMPANYING PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
The date of this prospectus supplement is January 12,
2004.
TABLE OF CONTENTS
You should rely only on the information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus. We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus supplement and the accompanying prospectus is accurate as of its date. Our business, financial condition, results of operations and prospects may have changed since then.
You should carefully read this prospectus supplement, the accompanying prospectus dated February 13, 2003, and the information incorporated into these documents before you invest in our common stock. To the extent any information contained in this prospectus supplement conflicts with any information contained in the accompanying prospectus, or any documents incorporated by reference prior to the date of this prospectus supplement, the information contained in this prospectus supplement shall control.
PROSPECTUS SUPPLEMENT
Page |
|
| The Company ......................................................................................................................................................................... | S-3 |
| The Offering ........................................................................................................................................................................... | S-3 |
| Recent Developments ............................................................................................................................................................. | S-3 |
| Risk Factors ........................................................................................................................................................................... | S-4 |
| Use of Proceeds ..................................................................................................................................................................... | S-4 |
| Material U.S. Federal Tax Considerations for Non-U.S. Holders of Common Stock ............................................................... | S-4 |
Plan of Distribution ................................................................................................................................................................. |
S-6 |
| Legal Matters ......................................................................................................................................................................... | S-6 |
| Experts ................................................................................................................................................................................... | S-6 |
Incorporation of Certain Documents By Reference .................................................................................................................. |
S-7 |
PROSPECTUS
Page |
|
| The Company ....................................................................................................................................................................... | 1 |
| Risk Factors ......................................................................................................................................................................... | 2 |
| Forward Statements .............................................................................................................................................................. | 9 |
| Use of Proceeds .................................................................................................................................................................... | 9 |
| Ratio of Earnings to Fixed Charges ........................................................................................................................................ | 9 |
| Description of Debt Securities ................................................................................................................................................ | 10 |
| Description of Common Stock ............................................................................................................................................... | 21 |
| Description of Preferred Stock .............................................................................................................................................. | 22 |
| Description of Warrants ......................................................................................................................................................... | 22 |
| Plan of Distribution ................................................................................................................................................................ | 24 |
| Legal Matters ........................................................................................................................................................................ | 25 |
| Experts ................................................................................................................................................................................. | 25 |
Where You Can Find More Information ................................................................................................................................ |
25 |
References in this prospectus supplement to "we," "us,"
"our," "the Company," and "Neurogen" mean Neurogen
Corporation unless otherwise expressly stated or the context otherwise requires.
S-2
THE COMPANY
Neurogen is a drug discovery and development company targeting new small molecule drugs to improve the lives of patients suffering from disorders with significant unmet medical needs including inflammation, pain, insomnia, depression, anxiety and obesity. We have generated a portfolio of new drug programs through our fully integrated drug discovery and development processes. Our Accelerated Intelligent Drug Discovery ("AIDD")™ process and our expertise in cellular functional assays enhance our ability to rapidly and cost effectively identify small molecule drug candidates. Small molecule drugs typically are suitable for oral administration as a pill, while large molecule drugs typically are administered by injection. We conduct research and development independently and, when advantageous, collaborate with leading pharmaceutical companies during the drug research and development process to obtain additional resources and to access complementary expertise. Currently, we have active collaborations with Merck, Pfizer and Aventis.
We have diversified our drug discovery and development efforts across a broad number of disease-related targets and employ a strategy designed to efficiently discover multiple drug candidates for each target. In addition, several of our programs focus on medical targets which are implicated in numerous, related disease states. Throughout the pharmaceutical industry the majority of all drug candidates fail to overcome all of the obstacles on the way to commercialization. Because of this high attrition rate, we believe that the true value of a drug discovery and development company's pipeline is most accurately measured by the company's ability to rapidly discover multiple generations of improved candidates within each of several programs. We believe that this ability to rapidly and systematically produce multiple generations of drug candidates in multiple programs is our most valuable asset. Although much smaller than major pharmaceutical companies, we have discovered ten small molecule drug candidates that we, together with our pharmaceutical company partners, have entered into human clinical trials.
Neurogen was incorporated in Delaware in September 1987 and commenced operations in July 1988. Our executive offices and research and development facilities are located at 35 Northeast Industrial Road, Branford, Connecticut 06405. Our telephone number is (203) 488-8201. We maintain a website at www.neurogen.com. The contents of our website are not part of this prospectus supplement.
THE OFFERING
Common stock offered by us ............................................................................................ |
1,783,252 shares |
| Common stock to be outstanding after this offering ............................................................ | 19,877,896 shares |
| Use of Proceeds ............................................................................................................... | We intend to use the proceeds from the offering for research and development and general corporate purposes. See "Use of Proceeds." |
Nasdaq National Market symbol ...................................................................................... |
NRGN |
The number of shares of common stock outstanding after this offering is based upon 18,094,644 shares outstanding as of January 7, 2004.
RECENT DEVELOPMENTS
Neurogen and Merck & Co., Inc. ("Merck") have formed an exclusive alliance, to research, develop and commercialize novel small molecule medicines which work by targeting the vanilloid receptor (VR1), a key integrator of pain signals in the nervous system. It is believed that in addition to playing a central role in many pain conditions, VR1 may also play a role in other disorders such as urinary incontinence.
The alliance enables Merck, through a subsidiary, and Neurogen to pool VR1 drug candidates previously discovered by each company and combine their ongoing VR1 programs to form a global research and development collaboration. The parties will form a joint steering committee to oversee the research collaboration. Merck will fund the research and development phases of the collaboration and will have the exclusive responsibility for the commercialization of collaboration drugs. The goal of the alliance is to rapidly provide patients with better medicines for pain and for disease states in which VR1 has been implicated.
S-3
Upon consummation of the collaboration, Merck will make a $15 million license fee payment to us and purchase the shares of common stock offered hereby at the average market price per share for the 25 trading days preceding regulatory clearance of the transaction. This regulatory clearance was obtained on December 29, 2003. In addition, during the first two years of the agreement, Merck will provide us with research funding and license maintenance payments totaling $12.0 million. Merck will have the right to extend the research program for up to three additional years, subject to certain required levels of funding and certain termination rights of Neurogen. We will be eligible to receive research, development, and approval milestone payments of up to $118 million for the successful commercialization of a collaboration drug for a single therapeutic indication. We will also be eligible to receive milestone payments for the approval of additional indications and the attainment of certain sales levels. Merck will pay us royalties on the sale of products from the collaboration.
For additional information concerning our collaboration with Merck, see our Form 8-K’s filed with the SEC on December 1, 2003 and December 8, 2003, which are incorporated by reference herein.
On January 13, 2004, Neurogen Corporation announced top-line results from its Phase IIa clinical trial for asthma using NGD 2000-1, the first oral C5a antagonist to be tested in humans for the treatment of asthma. In this exploratory trial, designed to evaluate the potential benefit of blocking the C5a receptor in patients with mild to moderate asthma, NGD 2000-1 did not demonstrate a therapeutic benefit with respect to predetermined endpoints.
The safety, pharmacokinetics, and efficacy of NGD 2000-1 for treatment of asthma were assessed in a randomized, double-blind, placebo controlled study of patients with mild to moderate asthma. The trial encompassed 142 patients in 16 clinical centers. Patients were dosed for 28 days with either placebo, 10 mg, 60 mg, or 100 mg of NGD 2000-1, twice daily. The primary endpoint for the trial measured Forced Expiratory Volume in one second (FEV-1), the most frequently used lung function index for assessing bronchoconstriction or bronchodilatation in asthmatics. Secondary endpoints included an assessment of disease signs and symptoms and the use of albuterol, a common rescue medication used by asthma patients.
RISK FACTORS
You should carefully review the information contained under the heading "Risk Factors" in the accompanying prospectus and the information concerning risks relating to our business in our Annual Report on Form 10-K for the fiscal year ended December 31, 2002, our Quarterly Reports on Form 10-Q for the quarters ended March 31, June 30 and September 30, 2003, as well as other information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus.
USE OF PROCEEDS
We intend to use the net proceeds from the sale of our common stock offered hereby for research and development and general corporate purposes.
MATERIAL U.S. FEDERAL TAX CONSIDERATIONS FOR
NON-U.S. HOLDERS OF COMMON STOCK
The following is a discussion of the material U.S. federal income and estate tax consequences of the ownership and disposition of our common stock by a beneficial owner of the stock that is a "non-U.S. holder". A "non-U.S. holder" of our common stock is a person or entity that, for U.S. federal income tax purposes, is a:
- non-resident alien individual (other than certain former citizens and
residents of the United States who are taxed as expatriates),
- foreign corporation, or
- foreign estate or trust.
This discussion does not address any tax consequences to any person other than a non-U.S. holder or tax consequences to any person arising under the laws of any state, local or foreign jurisdiction. The discussion also does not address all aspects of U.S. federal income and estate taxation that may be relevant to non-U.S. holders in light of their particular circumstances. Special rules not addressed in this discussion may apply, for example, to non-U.S. holders that are "controlled foreign corporations," "passive foreign investment companies," "foreign personal holding companies," individuals who are U.S. expatriates, partnerships and other pass-through entities and the partners or members of those entities, corporations that accumulate earnings to avoid U.S. federal income tax, banks or other financial institutions, insurance companies, persons that own or are deemed to own more than 5% of our stock, dealers in securities, traders in securities, tax-exempt entities, persons that holds our common stock as part of a straddle, hedge, conversion, synthetic, or constructive sale transaction or persons that do not hold our common stock as a "capital asset."
This discussion is based on the Internal Revenue Code of 1986, as amended (the "Code"), and administrative pronouncements, judicial decisions and final, temporary and proposed Treasury Regulations, changes to any of which after the date of this prospectus may affect the tax consequences described below. Prospective holders are urged to consult their tax advisors about the tax consequences to them of owning and disposing of common stock in light of their particular circumstances, including the consequences under the laws of any state, local or foreign jurisdiction that might apply.
S-4
Dividends
As discussed under "Risk Factors – We Do Not Expect To Pay Dividends on Our Common Stock," in the accompanying prospectus, we do not expect to pay dividends on our common stock for the foreseeable future. If we do pay a dividend, the gross amount of the dividend paid to a non-U.S. holder generally will be subject to withholding tax at a 30% rate or a reduced rate specified by an applicable income tax treaty. In order to obtain a reduced rate of withholding, a non-U.S. holder generally will be required to provide an Internal Revenue Service Form W-8BEN certifying its entitlement to benefits under the applicable treaty.
The withholding tax does not apply to dividends paid to a non-U.S. holder who provides an Internal Revenue Service Form W-8ECI, certifying that the dividends are effectively connected with the non-U.S. holder's conduct of a trade or business within the United States. Instead, the effectively connected dividends will be subject to regular U.S. income tax. A non-U.S. holder that is a corporation receiving effectively connected dividends may also be subject to an additional "branch profits tax" imposed at a 30% rate or a reduced rate specified by an applicable income tax treaty.
Gain on Disposition of Common Stock
A non-U.S. holder generally will not be subject to U.S. federal income tax on gain realized on a sale or other disposition of our common stock unless:
- the gain is effectively connected with a trade or business of the non-U.S.
holder in the United States,
- the non-U.S. holder is an individual who is present in the United States
for 183 days or more during the taxable year of disposition and certain other
requirements are met, or
- we are or have been a "U.S. real property holding corporation,”
as defined below, at any time within the five-year period preceding the disposition
or the non-U.S. holder's holding period, whichever period is shorter, and
our common stock has ceased to be traded on an established securities market
prior to the beginning of the calendar year in which the sale or disposition
occurs.
Generally, a corporation is a "U.S. real property holding corporation” if the fair market value of its United States real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. We believe that we are not, and do not anticipate becoming, a U.S. real property holding corporation.
Information Reporting Requirements and Backup Withholding
We must report annually to the Internal Revenue Service and to each non-U.S. holder the amount of dividends paid to such non-U.S. holder and the tax withheld with respect to those dividends, regardless of whether withholding was required. Copies of the information returns reporting those dividends and withholding may also be made available to the tax authorities in the non-U.S. holder's country of residence under the provisions of an applicable income tax treaty or other applicable agreements.
Backup withholding is imposed on certain payments to persons that fail to furnish the necessary identifying information to the payor. A non-U.S. holder generally will be subject to backup withholding tax with respect to dividends paid on common stock, currently at a 28% rate, unless the non-U.S. holder certifies its non-United States status.
The payment of proceeds of a sale of common stock effected by or through a United States office of a broker is subject to both backup withholding and information reporting unless a non-U.S. holder provides the payor with its name and address and certifies its non-United States status or such non-U.S. holder otherwise establishes an exemption. In general, backup withholding and information reporting will not apply to the payment of the proceeds of a sale of common stock by or through a foreign office of a broker. If, however, such broker is, for United States federal income tax purposes, a United States person, a controlled foreign corporation, a foreign person that derives 50% or more of its gross income for certain periods from the conduct of a trade or business in the United States, or, a foreign partnership that at any time during its tax year either is engaged in the conduct of a trade or business in the United States or has as partners one or more United States persons that, in the aggregate, hold more than 50% of the income or capital interest in the partnership, such payments will be subject to information reporting, but not backup withholding, unless such broker has documentary evidence in its records that the recipient is a non-U.S. holder and certain other conditions are met or the non-U.S. holder otherwise establishes an exemption.
S-5
Any amounts withheld under the backup withholding rules generally will be allowed as a refund or a credit against a non-U.S. holder's United States federal income tax liability provided the required information is furnished in a timely manner to the Internal Revenue Service.
Federal Estate Tax
An individual non-U.S. holder who is treated as the owner of, or has made certain lifetime transfers of, an interest in the common stock will be required to include the value of the stock in his gross estate for U.S. federal estate tax purposes, and may be subject to U.S. federal estate tax, unless an applicable estate tax treaty provides otherwise.
PLAN OF DISTRIBUTION
Under the terms and subject to the conditions contained in a purchase agreement dated as of November 24, 2003, Merck Sharp & Dohme Limited has agreed to purchase, and we have agreed to sell to them 1,783,252 shares of our common stock. Merck Sharp & Dohme Limited’s agreement to purchase the shares is guaranteed by Merck & Co., Inc. as guarantor.
The purchase agreement provides that the obligations of the purchaser to pay for and accept delivery of the shares of the common stock offered hereby are subject to the approval of certain legal matters by their counsel and to certain other conditions. The purchaser is obligated to take and pay for all of the shares of common stock offered hereby if any such shares are taken.
The shares of common stock sold in this offering will be traded on the Nasdaq National Market.
The expenses directly related to this offering, including legal, accounting, transfer agent and other miscellaneous fees and expenses, which are estimated to be less than $100,000, will be paid by us.
LEGAL MATTERS
Stephen R. Davis, Esq., our Executive Vice President and Chief Business Officer, will pass upon certain legal matters relating to our issuance and sale of the common stock. Milbank, Tweed, Hadley & McCloy LLP, New York, New York, our special counsel, will also pass upon certain legal matters relating to our issuance and sale of the common stock. Kevin McArdle, Legal Officer of Merck Sharp & Dohme Limited, and George Shiebler, Esq., Vice President and Assistant General Counsel of Merck & Co., Inc., will pass upon certain legal matters for the purchaser and the guarantor.
EXPERTS
The financial statements incorporated in this Prospectus by reference to the Annual Report on Form 10-K for the year ended December 31, 2002 have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, independent accountants, given on the authority of said firm as experts in auditing and accounting.
S-6
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The SEC allows us to "incorporate by reference” the information contained in documents that we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus supplement. Information in this prospectus supplement supersedes information incorporated by reference which we filed with the SEC prior to the date of this prospectus supplement, while information that we file later with the SEC will automatically update and supersede this information. We incorporate by reference the documents listed below and any future filings we will make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934:
- Our Annual Report on Form 10-K for the fiscal year ended December 31,
2002, including all material incorporated by reference therein;
- Our Quarterly Reports on Form 10-Q for the fiscal quarters ended March
31, 2003, June 30, 2003 and September 30, 2003; and
- Our Current Reports on Form 8-K, filed with the SEC on December 1, 2003,
December 8, 2003 and January 13, 2004.
S-7
PROSPECTUS

NEUROGEN CORPORATION
$75,000,000
NEUROGEN CORPORATION
DEBT SECURITIES
PREFERRED STOCK
COMMON STOCK
WARRANTS
We may offer and sell securities from time to
time in one or more offerings. This prospectus provides you with a general description
of the
securities we may offer.
Each time we sell securities, we will provide
a supplement to this prospectus that contains specific information about the
offering and the terms of the securities. The supplement may also add to, update
or clarify information contained in this prospectus. You should carefully read
this prospectus and any supplement before you invest in any of our securities.
We may offer and sell the following securities:
- debt securities, in one or more series, consisting of notes, bonds, debentures
or other evidences of indebtedness,
- preferred stock,
- common stock, and
- warrants.
INVESTING IN OUR SECURITIES INVOLVES
A HIGH DEGREE OF RISK.
SEE "RISK FACTORS" BEGINNING ON PAGE 2 OF THIS PROSPECTUS.
Our common stock is traded on the Nasdaq National Market under
the symbol "NRGN". Any common stock sold pursuant to this prospectus or any
prospectus supplement will be listed on that exchange, subject to official notice
of issuance. The prospectus supplement will state whether any other securities
offered thereby will be listed on a securities exchange.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION
HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ACCURACY
OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL
OFFENSE.
The date of this prospectus is February 13, 2003
TABLE OF CONTENTS
PAGE |
|
| THE COMPANY ............................................................................................................................................ | 1 |
| RISK FACTORS ............................................................................................................................................. | 2 |
| FORWARD-LOOKING STATEMENTS ........................................................................................................ | 9 |
| USE OF PROCEEDS ...................................................................................................................................... | 9 |
| RATIO OF EARNINGS TO FIXED CHARGES ............................................................................................ | 9 |
| DESCRIPTION OF DEBT SECURITIES ....................................................................................................... | 10 |
| DESCRIPTION OF COMMON STOCK ....................................................................................................... | 21 |
| DESCRIPTION OF PREFERRED STOCK .................................................................................................... | 22 |
| DESCRIPTION OF WARRANTS .................................................................................................................. | 22 |
| PLAN OF DISTRIBUTION ............................................................................................................................ | 24 |
| LEGAL MATTERS .......................................................................................................................................... | 25 |
| EXPERTS ......................................................................................................................................................... | 25 |
| WHERE YOU CAN FIND MORE INFORMATION ..................................................................................... | 25 |
--------------
We have filed a registration statement on Form
S-3 to register with the Securities and Exchange Commission the securities described
in this prospectus. This prospectus is part of that registration statement.
As allowed by the SEC's rules, this prospectus does not contain all of the information
you can find in the registration statement or the exhibits to the registration
statement. Please see "Where You Can Find More Information" on page 24.
You should rely only on the information contained
in this prospectus. We have not authorized anyone to provide you with information
different from that contained in this prospectus. The information contained
in this prospectus and the supplement to this prospectus is accurate only as
of the dates of their respective covers, regardless of the time of delivery
of this prospectus or any supplement to this prospectus or of any sale of our
securities.
THE COMPANY
Neurogen is a leading drug discovery
company. We engage in the discovery and development of a broad range of novel
small molecule compounds for pharmaceutical uses.
We have diversified our drug discovery and development efforts across a broad
number of disease-related biological targets and across multiple chemical series
from which we pursue drug candidates for each target. We have applied our fully
integrated drug discovery platform to establish a portfolio of new drug programs
in the areas of neuro-psychiatric disorders, inflammation, pain and metabolic
diseases. Our strategy is to advance a mix of proprietary drug programs independently
and, when advantageous, collaborate with world-class pharmaceutical companies
to obtain additional resources and to access complementary expertise.
Throughout the pharmaceutical industry the majority of all drug candidates fail
to overcome all of the obstacles on the way to commercialization. Because of
this high attrition rate, we believe that the true value of a drug discovery
company's pipeline is most accurately measured by the company's ability to rapidly
discover multiple generations of improved candidates within each of several
programs, rather than by the promise of any single compound in any one program.
We believe that this ability to rapidly and systematically produce multiple
generations of incrementally improved drug candidates in multiple programs is
our most valuable asset. Although we are much smaller than the well-known pharmaceutical
companies, we have discovered ten small molecule drug candidates (listed in
the table below) that we and our pharmaceutical company partners have taken
into human clinical trials. One of these candidates from our program for the
treatment of inflammatory disorders (candidate NGD 2000-1) is currently entering
Phase II human clinical trials. From our program for the treatment of insomnia,
our partner Pfizer Inc. is also developing in Phase I human studies a second
candidate (NGD 96-3). Eight of these candidates have been discontinued. The
ten candidates are:
| Drug Candidate | Receptor Target | Therapeutic Indication |
| NGD 91-1 | Gamma-AminoButyric Acid | Anxiety |
| NGD 91-2 | Gamma-AminoButyric Acid | Anxiety |
| NGD 91-3 | Gamma-AminoButyric Acid | Anxiety |
| NGD 94-1 | Dopamine | Schizophrenia |
| NGD 94-4 | Dopamine | Schizophrenia |
| NGD 95-1 | Neuropeptide Y | Obesity |
| NGD 96-1 | Gamma-AminoButyric Acid | Insomnia |
| NGD 96-3 | Gamma-AminoButyric Acid | Insomnia |
| NGD 97-1 | Gamma-AminoButyric Acid | Alzheimer's Disease |
| NGD 2000-1 | C5a anaphylatoxin | Inflammatory Disorders |
We are constantly working to gain and maintain
a competitive advantage in the process of discovering and developing new drug
candidates. As a result, we have generated a high-quality collection, or library,
of over 1.3 million potential drug compounds and have created powerful new drug
discovery and refinement technologies. The prime example of these new technologies
is our Accelerated Intelligent Drug Discovery (AIDD™) system. Our AIDD
system is an engine for the discovery of new drug leads and the optimization
of these leads to create drug candidates for clinical development. This system
also enables us to rapidly discover chemical leads to assess new gene-based
targets in which we are interested. Our AIDD system is a key factor contributing
to our belief that our small molecule drug discovery and development platform
is among the most advanced and efficient in the industry.
Neurogen was incorporated in Delaware in September
1987 and commenced operations in July 1988. Our executive offices and research
and development facilities are located at 35 Northeast Industrial Road, Branford,
Connecticut 06405. Our telephone number is (203) 488-8201. We maintain a website
at www.neurogen.com. The contents of our website are not part of this prospectus.
1
RISK FACTORS
Purchasing securities to be offered under this registration statement involves
a high degree of risk. You should consider carefully the following risks, together
with all other information included in this prospectus, before you decide to
purchase such securities. Please keep these risks in mind when reading this
prospectus, including any forward-looking statements appearing in this prospectus.
If any of the following risks actually occurs, our business, financial condition
or results of operations would likely suffer materially. As a result, the trading
price of our common stock may decline, the value of other securities offered
hereunder may decline and you could lose all or part of your investment.
THERE ARE RISKS RELATED TO THIS OFFERING THAT COULD RESULT IN SUBSTANTIAL
LOSSES FOR INVESTORS WHO DECIDE TO PURCHASE SECURITIES.
SECURITIES MARKET RISKS
THE SECURITIES WE ARE OFFERING, OTHER THAN OUR COMMON STOCK, DO NOT HAVE AND
MAY NOT DEVELOP AN ACTIVE PUBLIC MARKET, WHICH COULD DEPRESS THE RESALE PRICE
OF THE SECURITIES.
The securities we are offering, other than our common stock, will be new issues
of securities for which there is currently no trading market. We cannot predict
whether an active trading market for the securities will develop or be sustained.
If an active trading market were to develop, the securities could trade at prices
that may be lower than the initial offering price of the securities.
THE PRICE OF OUR COMMON STOCK OR OTHER SECURITIES OFFERED BY THIS PROSPECTUS
MAY DECLINE.
The trading price of our common stock or other securities offered by this prospectus
may decline to below the price at which such stock or other securities may be
sold hereunder.
The market prices for securities of biotechnology companies, including ours,
have historically been highly volatile. The market has, from time to time, experienced
significant price and volume fluctuations that are unrelated to the operating
performance of particular companies. The market price of our common stock or
other securities may fluctuate significantly due to a variety of factors, including:
- the results of preclinical testing and clinical trials by us or our competitors;
- technological innovations or new therapeutic products;
- governmental regulation;
- developments in patent or other proprietary rights;
- litigation;
- public concern as to the safety of products developed by us or others;
- comments by securities analysts; and
- general market conditions in our industry.
IF OUR STOCKHOLDERS SELL SUBSTANTIAL AMOUNTS OF OUR COMMON STOCK, THE
MARKET PRICE OF OUR COMMON STOCK MAY FALL.
If our stockholders sell substantial amounts of
our common stock including shares issued upon the exercise of outstanding options
and warrants, the market price of our common stock may fall. These sales also
might make it more difficult for us to sell equity or equity-related securities
in the future at a time and price that we deem appropriate.
WE DO NOT EXPECT TO PAY DIVIDENDS ON OUR COMMON STOCK.
We have never declared or paid dividends on our
common stock in the past and we do not expect to pay dividends on our common
stock for the foreseeable future.
2
RISKS RELATED TO OUR BUSINESS
WE HAVE NOT YET ACHIEVED PROFITABILITY AND EXPECT TO INCUR LOSSES FOR
THE FORESEEABLE FUTURE.
We have been unprofitable in most years since
our inception in 1987 and have incurred a cumulative net loss of approximately
$86.9 million through September 30, 2002. In 2001 and 2000, we lost $25.4 million
and $15.5 million, respectively. These losses are primarily attributable to
costs we have incurred in the discovery and development of our new drug candidates.
We recognized a net loss of $19.2 million for the nine months ended September
30, 2002 as compared with a net loss of $20.2 million for the same period in
2001. The decrease in net loss is primarily due to the recognition in 2002 of
license fees recognized from the conclusion of a technology transfer agreement
with Pfizer Inc., that were offset in part by an increase in research and development
and general and administrative expenses and a decrease in investment income
in 2002. Research and development costs and general and administrative expenses
are expected to increase over the next several years. In 2001, research and
development costs, net of non-cash stock compensation charges, increased 23%
to $34.5 million from $28.0 million in 2000. The 2000 amount represented a 17%
increase over the 1999 amount of $24.0 million. As a result, we are likely to
incur significant and increasing losses over at least the next several years.
We are unable to predict when, or if, we will become profitable. If we continue
to incur operating losses, we may eventually be unable to continue our operations.
OUR ONLY CURRENT REVENUE SOURCES COME FROM OUR COLLABORATIONS AND WE
ARE UNLIKELY TO DERIVE ANY REVENUES FROM PRODUCT SALES IN THE FORESEEABLE FUTURE.
Research funding to date has come from three collaborative
research agreements and one technology transfer agreement with Pfizer, one collaboration
with Aventis Pharmaceuticals, and one collaboration with Schering-Plough. Research
funding payments under our current drug collaboration agreement with Aventis
are currently scheduled to end by December 1, 2004. Payments under our technology
transfer agreement with Pfizer expired upon the scheduled conclusion of the
agreement in June 2002. We have concluded the research portions of our gamma-aminobutyric
acid and neuropeptide Y agreements with Pfizer and research funding to us under
those agreements has come to its scheduled conclusion. We concluded our collaboration
with and stopped receiving revenues from Schering-Plough at the end of June
1998. Our license agreement with American Home Products, under which we received
$0.8 million for 37,442 shares of common stock and a $0.8 million license fee
but no research funding, terminated in January 1999.
The company recognized $2.9 million in research
revenue under the 1992 and 1994 Pfizer agreements in the gamma-aminobutyric
acid program in 2001. Similar revenues will not be recognized in future years
due to the conclusion of these agreements at the end of 2001. The company also
recognized $8.3 million in license fees in 2001 and expects to recognize $9.4
million in license fees in 2002 under the 1999 Pfizer Technology Transfer Agreement.
Similar revenues will not be occurring in future years. In addition to the $9.4
million in revenue recognition under the 1999 Pfizer Technology Transfer Agreement,
the Company expects to recognize approximately $6.4 million in 2002 under our
current collaboration agreement with Aventis.
We have not achieved and do not expect to achieve
revenues from product sales for several years, if at all. Revenue from product
sales depends on whether we or one of our collaborative partners can successfully
complete product development of, obtain required regulatory approvals for, and
commercialize our products. If we are unable to commercialize any drug products,
we will never achieve product revenues and may eventually be unable to continue
our operations. This result would cause investors to lose all or a substantial
portion of their investment.
ALL OF OUR DRUG CANDIDATES ARE STILL BEING DEVELOPED AND MAY NOT RESULT
IN COMMERCIAL PRODUCTS FOR A NUMBER OF YEARS OR AT ALL.
We are in the early stage of product development
and we do not expect to have any products resulting from our research efforts
commercially available for a number of years, if at all. To date, we have stopped
developing eight compounds which had previously been in clinical development.
Currently, we have several compounds in preclinical development, one compound
just entering Phase II human clinical trials and one compound in Phase I human
clinical trials. All of our compounds currently being developed, whether in
human clinical trials or not, will require significant additional research,
development and testing before they can be commercialized. We cannot accurately
predict the time required or the cost involved in commercializing any new drug.
In addition, developing new drugs is an extremely uncertain process, and unanticipated
developments such as clinical or regulatory delays, unexpected side effects
in test patients, or ineffectiveness would slow or prevent the development of
a product. If we are unable to commercialize any drug products, we will never
achieve product revenues and may eventually be unable to continue our operations.
This result would cause investors to lose all or a substantial portion of their
investment.
3
THE DRUG TESTING PROCESS IS LONG, COSTLY, AND UNCERTAIN
AND MOST DRUG CANDIDATES FAIL TO BE APPROVED. EVEN IF APPROVED FOR USE IN HUMANS,
A DRUG MAY PROVE TO BE UNSAFE OR INEFFECTIVE.
A potential drug candidate must go through extensive
preclinical (animal) and clinical (human) trials to prove that the drug is safe
and effective before it can be commercialized. This extensive testing takes
several years, is quite expensive, and more often than not leads to the conclusion
that a drug candidate is not suitable for commercialization. Moreover, even
if early drug testing appears positive, later testing or even the results of
usage after commercialization may preclude further use of a drug. The results
of preclinical tests performed on animals are not always accurate predictors
of the safety, effectiveness, or suitability of drugs in humans. Similarly,
the results of initial clinical trials do not necessarily accurately predict
the results that will be obtained in the later stages of clinical trials. The
appearance of adverse side effects or a lack of effectiveness in clinical trials
could interrupt, delay or result in termination of clinical testing of the product
in question and could ultimately prevent its approval by the United States Food
and Drug Administration (the FDA) or foreign regulatory authorities. Either
the FDA or we may suspend clinical trials at any time if the FDA or we believe
that the individuals participating in the trials are being exposed to unacceptable
health risks. Even products approved by the FDA or foreign regulatory authorities
may later exhibit adverse side effects that prevent their widespread use or
necessitate their withdrawal from the market. As a result, our drug candidates
may prove to be unsafe or ineffective in humans, produce undesirable side effects,
or, fail to get through the testing phases to commercialization. With the exception
of our two lead candidates, NGD 2000-1 (our lead candidate in our inflammation
program) and NGD 96-3 (our lead candidate in our insomnia program), none of
our current compounds has received regulatory clearance for any stage of clinical
trials in humans.
WE HAVE LIMITED EXPERIENCE IN THE CLINICAL PROCESS AND WE RELY HEAVILY
ON OUR COLLABORATIVE PARTNERS FOR RESEARCH AND DEVELOPMENT FUNDING AND COMMERCIALIZATION.
We depend on our collaborative partners to fund
a significant portion of our research and development expenses and to manufacture
and market products resulting from our collaborations. In the fiscal years ended
December 31, 1999, 2000, 2001 and the nine-month period ended September 30,
2002, the Company incurred $24.0 million, $28.0 million, $34.5 million and $27.4
million in research and development expenses (excluding stock compensation expense)
and earned $9.7 million, $9.2 million, $3.1 million and $3.5 million respectively,
in research and development revenue from corporate partners. Because we have
limited experience conducting clinical trials, we also depend on our collaborative
partners with respect to regulatory filings relating to, and the clinical testing
of, compounds developed under our collaborations. In particular, we depend on
Pfizer and Aventis to conduct clinical trials for compounds on which we collaborate,
including our lead compound from our Pfizer collaborations, NGD 96-3. Our reliance
on collaborative partners exposes us to many risks, including the following:
- That a collaborator will halt, delay, or repeat clinical trials;
- That a collaborator will alter the amount or timing of resources dedicated
to our collaboration;
- That a collaborator will dispute our rights under an agreement;
- That a collaborator will attempt to independently develop a competing drug
on its own or in conjunction with a third party;
- That existing collaboration agreements will not be extended;
- That a collaborator will not continue to develop a drug candidate after a
collaboration agreement has ended; and
- That a collaborator will breach or terminate an agreement with us.
If any of these risks were to occur, the research program in question, and possibly our business, would suffer. Our existing collaborations may be unsuccessful and we may not receive any future milestone payments. If our existing collaborations are not continued or are unsuccessful, our product development efforts and consequently business would suffer. Delays or discontinuation of any of our collaborative programs could significantly delay and decrease the probability of our ever achieving product revenues. This could negatively impact our ability to access and our cost of capital. If our collaborative partners do not continue the development of our compounds under our collaborations, we may not be able to do so on our own. Under our current collaborations, each of Pfizer and Aventis control, subject to certain diligence requirements, the determination of when and if to advance compounds in the clinical process. In addition, we may not be able to find suitable partners for any new collaborations we may seek to enter. Any new collaborations would likely be subject to some or all of the same risks as our existing collaborations.
4
A CONSEQUENCE OF ENTERING INTO COLLABORATIVE ARRANGEMENTS IS THAT OUR
POTENTIAL UPSIDE IS SMALLER IF A SUCCESSFUL PRODUCT EMERGES THAN IF WE SUCCESSFULLY
COMMERCIALIZED A PRODUCT ON OUR OWN.
We have entered into strategic collaborations
with large pharmaceutical companies to develop and commercialize new drugs.
Under our collaborations with Pfizer, we have, with limited exceptions, granted
Pfizer the exclusive worldwide license to manufacture, use and sell products
developed under the Pfizer agreements. Under our collaboration with Aventis,
we have granted Aventis the exclusive worldwide license to manufacture, use
and sell products developed under the Aventis agreement. While these collaborations
have allowed us to recoup our research and development expenses and avoid risking
our own capital on these activities, they have, in most cases, limited our upside
to receiving only royalties based on net sales levels should a successful drug
result. Were we to successfully develop and commercialize a drug completely
on our own, however, our potential upside would be even larger.
WE PERIODICALLY EXPLORE NEW ALLIANCES THAT MAY NEVER MATERIALIZE OR
MAY FAIL.
We periodically explore a variety of possible
partnerships or alliances in an effort to gain access to additional complimentary
resources. At the current time, we cannot predict what form such a partnership
or alliance might take. To date, our only experience working with other companies
has come from our drug program collaborations and our single AIDD technology
transfer agreement with large pharmaceutical companies. We have no experience
managing a joint venture, merger or acquisition. We may not be able to find
a suitable partner for any such alliance on favorable terms or at all. If we
do find a suitable partner, we may not have the financial capability to conclude
an agreement. Or, if we do form a partnership or other alliance to gain access
to additional resources, the venture may be unsuccessful or it may not achieve
its intended purposes.
There have been a significant number of recent
business combinations among large pharmaceutical companies that have resulted
in a reduced number of potential future corporate collaborators. If business
combinations involving our corporate collaborators were to occur, the effect
could be to diminish, terminate or cause delays in one or more of our corporate
collaborations.
WE ARE NOT CERTAIN ABOUT HOW MUCH CAPITAL WE MAY NEED AND WE MAY HAVE
DIFFICULTY RAISING NEEDED CAPITAL IN THE FUTURE ON FAVORABLE TERMS OR AT ALL.
We have spent and will continue to spend substantial funds to complete the research,
development and clinical testing of our products. We will need additional funds
for these purposes, to establish additional clinical- and commercial-scale manufacturing
arrangements and to provide for the marketing and distribution of our products.
We may not be able to acquire additional funds on commercially reasonable terms
or at all. If we cannot acquire adequate funds, we may have to delay, reduce
the scope of or eliminate one or more of our research or development programs.
Such a reduction could concentrate our risks in fewer programs.
We believe that our cash, cash equivalents and marketable securities, plus future
scheduled payments under the Aventis agreement, will be adequate to satisfy
our capital needs into at least early 2005. However, our actual capital requirements
will depend on many factors, including:
- continued progress of our research and development programs;
- our ability to market and distribute any products we develop and to establish
new collaborative and licensing arrangements;
- changes in our existing collaborative relationships;
- progress with preclinical studies and clinical trials;
- the time and costs involved in obtaining regulatory clearance;
- the costs involved in preparing, filing, prosecuting, maintaining and enforcing
patent claims; and
- competing technological and market developments.
We may seek to raise any necessary additional funds through equity or debt financings, collaborative arrangements with corporate partners or other sources which may dilute the interest our existing stockholders have in our company. In addition, in the event that we obtain additional funds through arrangements with collaborative partners or other sources, these arrangements may require us to give up rights to some of our technologies, product candidates or products under development that we would otherwise seek to develop or commercialize ourselves.
5
WE FACE RAPID TECHNOLOGICAL CHANGE AND INTENSE COMPETITION.
The biopharmaceutical industry is highly competitive
and subject to rapid and substantial technological change. Developments by others
may render our products under development or our technologies noncompetitive
or obsolete. We may be unable to keep pace with technological developments or
other market factors. Technological competition in the industry, principally
from major pharmaceutical companies, but also from biotechnology companies,
universities, governmental entities and others diversifying into the field is
intense and is expected to increase. Our competitors may develop products that
are safer, more effective or less costly than any products we may develop or
may be able to complete their development more quickly. Our most advanced clinical
programs focus on neuro-psychiatric and inflammatory disorders and based on
our review of patent filings and information from industry sources, we believe
that most of the major pharmaceutical companies have drug programs to compete
with ours. These companies include Merck, Eli Lilly, Aventis, Glaxo-SmithKline,
Bristol-Myers, Squibb and Pfizer and there are likely others. Many of these
entities have significantly greater research and development capabilities than
we do, as well as substantially more marketing, manufacturing, financial and
managerial resources. In addition, acquisitions of, or investments in, competing
development-stage pharmaceutical or biotechnology companies by large corporations
could increase such competitors' financial, marketing, manufacturing and other
resources. If a competitor were to develop and successfully commercialize a
drug similar to one we were working on before us, it would put us at a significant
competitive disadvantage.
WE ARE SUBJECT TO STRICT GOVERNMENTAL REGULATION. IF WE CANNOT OBTAIN
PRODUCT APPROVALS OR IF WE CANNOT COMPLY WITH ONGOING GOVERNMENTAL REGULATIONS
OUR BUSINESS COULD SUFFER.
Our products are subject to extensive regulation
and review by numerous federal, state and local government agencies both in
the United States and in other countries where we intend to test and market
our products. The process by which we obtain regulatory approval to market a
product involves substantial cost and can take many years. The data we obtain
from preclinical and clinical trials may be subject to varying interpretations
which can delay, limit or prevent the approval of the relevant governmental
authority. If there are delays and costs in obtaining regulatory approvals,
our product development efforts and consequently our business could suffer.
Agencies, such as the FDA, may change the end points for clinical trials once
they have begun, clinical data may not be accepted by the FDA or similar agencies,
or approvals may not be granted on a timely basis, if at all. Even if we obtain
regulatory approval of a drug, the approval may include limitations and restrictions
on the drug's use. In addition, we would be subject to continual review by the
government and any subsequent discovery of previously unrecognized problems
could result in restrictions being placed on either us or our products. These
restrictions could include an order to withdraw a product from the market. The
failure to comply with applicable regulatory requirements can, among other things,
result in fines, suspension of regulatory approvals, product recalls, seizure
of products, operating restrictions and criminal prosecution.
WE MAY NOT BE ABLE TO PROTECT OUR INTELLECTUAL PROPERTY.
Our success depends, in part, on our ability to
obtain patents, maintain trade secrets and operate without infringing on the
intellectual property rights of third parties. We file patent applications both
in the United States and in foreign countries to protect both our products and
our processes. The patent position of biotechnology and pharmaceutical firms
is highly uncertain and involves many complex legal and technical issues. Our
patent applications may not be successful or our current or future patents may
not afford us protection against our competitors. It is possible that our patents
will be successfully challenged or that patents issued to others may preclude
us from commercializing our products. Litigation to establish the validity of
patents, to defend against infringement claims or to assert infringement claims
against others can be lengthy and expensive. Moreover, much of our expertise
and technology cannot be patented. We also rely heavily on trade secrets (for
example, our AIDD™ system is not patented, but its proprietary elements
are protected as trade secrets) and confidentiality agreements with collaborators,
advisors, employees, consultants, vendors and other service providers. It is
possible that these agreements may be breached or that our trade secrets may
otherwise become known or be independently discovered by competitors. Our product
development efforts and consequently our business would suffer if our competitors
were able to learn our secrets or if we were unable to protect our intellectual
property.
6
WE ARE SUBJECT TO UNCERTAINTIES REGARDING HEALTH CARE REIMBURSEMENT
AND REFORM.
The continuing efforts of the government, insurance
companies, health maintenance organizations and other payers of healthcare costs
to contain or reduce costs of health care may affect our future revenues and
profitability, the future revenues and profitability of our potential customers,
suppliers and collaborative partners, and the availability of capital. For example,
in certain foreign markets, pricing or profitability of prescription pharmaceuticals
is subject to government control. In the United States, both the federal and
state governments will likely continue to focus on health care reform, the cost
of prescription pharmaceuticals and reform of the Medicare and Medicaid systems.
While we cannot predict whether any such proposals will be adopted, the announcement
or adoption of such proposals could negatively impact our business, financial
condition and results of operations.
Our ability to market our products successfully
will depend, in part, on the extent to which appropriate reimbursements for
the cost of our products and related treatments are available from governmental
authorities, private health insurers and other organizations, such as HMOs.
Significant uncertainty exists as to the reimbursement status of newly approved
healthcare products. Third-party payers, including Medicare, are constantly
challenging the prices charged for medical products and services. If third-party
payers institute cost containment measures or fail to approve our products for
reimbursement, our sales will suffer, as patients will opt for a competing product
that is approved for reimbursement.
OUR BUSINESS DEPENDS ON THE RETENTION OF A TEAM OF HIGHLY-QUALIFIED
MANAGEMENT AND TECHNICAL PERSONNEL.
While we do not rely on any single individual
or group of individuals, our success to date has depended on the skills of our
management and scientific personnel. We do not maintain key person life insurance
for any of our personnel. We believe our future success will depend, in large
part, on our ability to recruit and retain the services of skilled management
and technical personnel. We face significant competition for such individuals
from other companies, academic institutions, government entities and other organizations.
In particular, there is currently a shortage of qualified Ph.D. chemists and
drug metabolism scientists in the industry. If we cannot attract or retain these
key personnel our business would not remain competitive. We have employment
agreements with five of our executive officers.
WE RELY HEAVILY UPON THIRD PARTIES FOR OUR MANUFACTURING REQUIREMENTS.
To complete our clinical trials and to commercialize
our product candidates we need access to, or development of, facilities to manufacture
a sufficient supply of our product candidates. We depend on our collaborators
or third parties for the manufacture of compounds for pre-clinical, clinical
and commercial purposes in their FDA-approved manufacturing facilities. Our
products may be in competition with other products for access to these facilities.
Consequently, our products may be subject to manufacturing delays if collaborators
or outside contractors give other products greater priority than our products.
For this and other reasons, our collaborators or third parties may not be able
to manufacture these products in a cost-effective or timely manner. If not performed
in a timely manner, the clinical trial development of our product candidates
or their submission for regulatory approval could be delayed, and our ability
to deliver products on a timely basis could be impaired or precluded. We may
not be able to enter into any necessary third-party manufacturing arrangements
on acceptable terms, if at all. Our current dependence upon others for the manufacture
of our products may reduce our future profit margin and limit our ability to
commercialize products on a timely and competitive basis. We do not intend to
develop or acquire facilities for the manufacture of product candidates for
clinical trials or commercial purposes in the foreseeable future. In each of
our ongoing collaborations, either Aventis or Pfizer is responsible for manufacturing
or obtaining clinical and commercial supplies of pharmaceutical compounds. In
our un-partnered C5a anaphylatoxin anti-inflammatory program we utilize third
parties to prepare and formulate pharmaceutical compounds for use in clinical
studies. To date, these third parties have been CarboGen Holding AG of Aarau,
Switzerland, and AAI International of Wilmington, NC.
WE LACK MARKETING AND SALES EXPERIENCE.
We currently have no marketing, sales or distribution
efforts and, currently, we intend to rely primarily on existing or future collaborative
partners for this expertise if one of our products is successfully commercialized.
Therefore, to service markets for any areas in which we have retained sales
and marketing rights or in the event that any of our collaborative agreements
is terminated, we must develop a sales force with technical expertise. We have
no experience in developing, training or managing a sales force. We will incur
substantial additional expenses in developing, training and managing this sales
force. We may be unable to build such a sales force, the cost of establishing
such a sales force may exceed any product revenues, or our direct marketing
and sales efforts may be unsuccessful. In addition, we compete with many other
companies that currently have extensive and well-funded marketing and sales
operations. Our marketing and sales efforts may be unable to compete successfully
against such other companies. Moreover, even if we or one of our partners is
able to bring a product to market, it is possible that these products will not
gain acceptance among physicians, patients or third-party payers.
7
OUR BUSINESS EXPOSES US TO PRODUCT LIABILITY CLAIMS.
We face an inherent risk of exposure to product
liability claims in the event that the use of one of our products is alleged
to have caused an adverse effect on patients. This risk exists for products
being tested in human clinical trials, as well as for products that receive
regulatory approval for commercial sale. Manufacturers of pharmaceuticals have
been the subject of significant product liability litigation and we cannot assure
you that we will not be threatened with or become subject to such a claim. We
maintain limited product liability insurance for compounds we are testing in
clinical trials. We currently maintain liability insurance of $5.0 million in
coverage for the clinical trials that we conduct. Our partners indemnify us,
with certain exceptions, for collaborative compounds they are testing in clinical
trials. We intend to seek additional product liability insurance coverage if
and when our products are commercialized. We may not, however, be able to obtain
such insurance at acceptable costs, if at all, or such coverage, if obtained,
may not be adequate to cover any claims. If we cannot obtain sufficient insurance
coverage at an acceptable cost or otherwise protect against potential product
liability claims we could be prevented from commercializing our products. Or,
if we are subject to a product liability claim where claims or losses exceed
our liability insurance coverage and our ability to pay, we may go out of business.
OUR BUSINESS INVOLVES HAZARDOUS MATERIALS AND THE RISK OF ENVIRONMENTAL
LIABILITY.
As with many biotechnology companies, in connection
with our research and development activities, we are subject to federal, state
and local laws, rules, regulations and policies governing the use, generation,
manufacture, storage, air emission, effluent discharge, handling and disposal
of certain materials, biological specimens and wastes. Although we believe that
we have complied with the applicable laws, regulations and policies in all material
respects and have not been required to correct any noncompliance which is material
to our business, we may have to incur significant costs to comply with environmental
and health and safety regulations in the future. Our research and development
involves the controlled use of hazardous materials, including but not limited
to certain hazardous chemicals and radioactive materials. Although we believe
that our safety procedures for handling and disposing of such materials comply
with the standards prescribed by state and federal regulations, we cannot completely
eliminate the risk of accidental contamination or injury from these materials.
In the event of such an occurrence, we could be held liable for any damages
that result and any such liability could possibly exceed our resources.
RISKS RELATED TO SIGNIFICANT STOCKHOLDERS
If our directors, officers and largest stockholders
chose to act together, they would be able to control our management and operations,
potentially acting in their best interest and not necessarily those of other
stockholders.
As of September 30, 2002, our directors, officers
and holders of 5% or more of our outstanding common stock and their affiliates
beneficially owned approximately 70% of our common stock. Accordingly, if they
chose to act together, they collectively would have the ability to determine
the election of all of our directors and to determine the outcome of most corporate
actions requiring stockholder approval. They might exercise this ability in
a manner that advances their best interests and not necessarily those of other
stockholders.
In particular, as of September 30, 2002, accounts
beneficially owned by the Tisch Family Interests and managed by Felix J. Baker
and Julian C. Baker, two of our directors, represent in the aggregate approximately
20.9% of our outstanding common stock. In addition, Pfizer Inc., one of our
collaborative partners, owned 15.9% and three institutional investors each owned
11.9%, 11.1% and 5.9%, respectively, of our common stock. Except for Pfizer
Inc., none of our major shareholders are subject to any standstill or other
agreement limiting their ability to acquire additional shares of our capital
stock and may in the future, through open market purchases or otherwise, acquire
additional shares of our common stock.
8
FORWARD-LOOKING STATEMENTS
Some of the statements under "The Company," "Risk Factors" and elsewhere included or incorporated by reference in this prospectus constitute forward-looking statements. These statements relate to future events or our future financial or business performance and are identified by terminology such as "may," "might," "will," "should," "expect," "scheduled," "plan," "intend," "anticipate," "believe," "estimate," "potential," or "continue" or the negative of such terms or other comparable terminology. In evaluating these statements, you should specifically consider various factors, including the risks outlined under "Risk Factors." These factors, among others, may cause actual events or our actual performance to differ materially from any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
USE OF PROCEEDS
Except as otherwise described in the prospectus supplement relating to an offering of securities, we currently intend to use the net proceeds from the sale of securities offered pursuant to this prospectus and any prospectus supplement for research and development and general corporate purposes. We may also use some or all of the net proceeds to acquire or invest in businesses, products and technologies that are complementary to our own. Pending these uses, we intend to invest the net proceeds in investment-grade, interest-bearing securities.
RATIO OF EARNINGS TO FIXED CHARGES
Our earnings were insufficient to
cover fixed charges in each of the years in the five-year period ended December
31, 2001 and in the nine-month period ended September 30, 2002. "Earnings" consist
of loss before income taxes, excluding the cumulative effect of a change in
accounting principle, plus fixed charges and capitalized interest amortization
less capitalized interest, and "fixed charges" consist of interest and the amortization
of debt issuance costs incurred and the portion of rental expense deemed by
us to be representative of the interest factor of rental payments under leases.
The extent to which earnings were insufficient to cover fixed charges is as
follows:
Nine Months |
|||||||
|
Years Ended December 31, |
Ended |
||||||
1997 |
1998 |
1999 |
2000 |
2001 |
September 30, 2002 |
||
| |
|
||||||
(in thousands) |
|||||||
Deficiency of earnings |
$257 |
$9,458 |
$14,632 |
$15,127 |
$26,683 |
$19,502 |
|
For the periods indicated above, we had no outstanding shares of preferred stock
with required dividend payments. Therefore, the ratios of earnings to fixed
charges and preferred stock dividends are identical to the ratios presented
in the table above.
9
DESCRIPTION OF DEBT SECURITIES The
debt securities will be issued under an indenture between us and a bank or trust
company which will be identified in a prospectus supplement, as trustee. The
indenture provides for the issuance from time to time of debt securities in
an unlimited dollar amount and an unlimited number of series.
The following description of the terms of the
debt securities summarizes the material terms that will apply to the debt securities.
The description is not complete, and we refer you to the indenture, a copy of
which is attached as an exhibit to the registration statement of which this
prospectus is a part. For your reference, in several cases below we have noted
the section in the indenture that the paragraph summarizes. Capitalized terms
used in this section are defined under "Defined Terms." The referenced sections
of the indenture are incorporated by reference in the following summary. Prospective
purchasers of debt securities should be aware that special U.S. federal income
tax, accounting and other considerations may be applicable to instruments such
as the debt securities. The prospectus supplement or term sheet relating to
an issue of debt securities will describe these considerations, if they apply.
Specific Terms of Each Series
Each time that we issue a new series of debt securities, the prospectus supplement or term sheet relating to that new series will specify the particular amount, price and other terms of those debt securities. These terms may include:
- the title of the debt securities;
- any limit on the total principal amount of the debt securities;
- the date or dates on which the principal of the debt securities will be
payable or their manner of determination;
- the interest rate or rates of the debt securities; the date or dates from
which interest will accrue on the debt securities; and the interest payment
dates and the regular record dates for the debt securities; or, in each case,
their manner of determination;
- the place or places where the principal of and premium and interest on
the debt securities will be paid;
- the period or periods within which, the price or prices at which and the
terms on which any of the debt securities may be redeemed, in whole or in
part at our option, and any remarketing arrangements;
- the terms on which we would be required to redeem, repay or purchase debt
securities required by any sinking fund, mandatory redemption or similar provision;
and the period or periods within which, the price or prices at which and the
terms and conditions on which the debt securities will be so redeemed, repaid
or purchased in whole or in part;
- the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any whole multiple thereof;
10
- the portion of the principal amount of the debt securities that is payable on the declaration of acceleration of the maturity, if other than their principal amount; these debt securities could include original issue discount, or OID, debt securities or indexed debt securities, which are each described below;
- whether and under what circumstances we will pay additional amounts under
any debt securities held by a person who is not a U.S. person for tax payments,
assessments or other governmental charges and whether we have the option to
redeem the debt securities which are affected by the additional amounts instead
of paying the additional amounts;
- the form in which we will issue the debt securities, whether registered,
bearer or both, and any restrictions on the exchange of one form of debt securities
for another and on the offer, sale and delivery of the debt securities in
either form;
- the terms of any debt securities that may be converted into equity securities,
including conversion rate and rate adjustment provisions;
- whether the debt securities will be issuable as global securities;
- whether the amounts of payments of principal of, premium, if any, and interest,
if any, on the debt securities are to be determined with reference to an index,
formula or other method, and if so, the manner in which such amounts will
be determined;
- if the debt securities are issuable in definitive form upon the satisfaction
of certain conditions, the form and terms of such conditions;
- any trustees, paying agents, transfer agents, registrars, depositories
or similar agents with respect to the debt securities;
- any additions or deletions to the terms of the debt securities with respect
to the events of default or covenants governing the debt securities;
- the foreign currency or units of two or more foreign currencies in which
payment of the principal of and premium and interest on any debt securities
will be made, if other than U.S. dollars, and the holders' right, if any,
to elect payment in a foreign currency or foreign currency unit other than
that in which the debt securities are payable;
- whether and to what extent the debt securities are subject to defeasance
on terms different from those described under "- Defeasance of Indenture;"
and
- any other terms of the debt securities that are not inconsistent with the indenture.
(section 301)
We may issue debt securities as OID debt securities. OID debt securities bear no interest or bear interest at below-market rates and are sold at a discount below their stated principal amount. If we issue OID debt securities, the prospectus supplement or term sheet will contain the issue price, the rate at which interest will accrete, and the date from which such interest will accrete on the OID debt securities.
We may also issue indexed debt securities. Payments of principal of, and premium and interest on, indexed debt securities are determined with reference to the rate of exchange between the currency or currency unit in which the debt security is denominated and any other currency or currency unit specified by us, to the relationship between two or more currencies or currency units or by other similar methods or formulas specified in the prospectus supplement or term sheet.
11
Ranking
We may issue unsecured and unsubordinated debt securities that will rank equally
with all our other unsecured and unsubordinated debt or we may issue unsecured
and subordinated debt securities that will rank junior to our unsecured unsubordinated
debt and equally with all our other unsecured and subordinated debt. As of September
30, 2002, the Company had secured loans outstanding of $4,747,000 with Connecticut
Innovations, Inc. and $16,625,000 with Webster Bank that will rank senior to
the debt we may issue under this registration statement. See "-Subordination".
Form and Denomination
The prospectus supplement or term sheet will describe the form which the debt
securities will have, including insertions, omissions, substitutions and other
variations permitted by the indenture and any legends required by any laws,
rules or regulations. (section 201) We will issue debt securities in denominations
of $1,000 and whole multiples thereof, unless the prospectus supplement or term
sheet states otherwise. (section 302)
Payment
We will pay principal of and premium and interest on our registered debtsecurities
at the place and time described in the debt securities. We will pay installments
of interest on any registered debt security to the person in whose name the
registered debt security is registered at the close of business on the regular
record date for these payments. We will pay principal and premium on registered
debt securities only against surrender of these debt securities. (section 1001)
If we issue debt securities in bearer form, the prospectus supplement or term
sheet will describe where and how payment will be made.
Material Covenants
The indenture includes the following material covenants:
Lien on assets
We will not, nor will we permit any Restricted Subsidiary to, issue or assume
any Indebtedness secured by a Lien upon any Property we or any Restricted Subsidiary
now own or acquire in the future without equally and ratably securing the debt
securities.
This restriction does not apply, however, to any of the following:
- Liens existing on the date of the indenture;
- Permitted Liens;
- Liens on any property or asset that existed at the time when we or any
subsidiary acquired that property or asset;
- Liens on fixed or capital assets acquired, constructed or improved by us or
any of our subsidiaries that are incurred before or within 180 days of
acquiring, constructing or improving the asset and that do not exceed the
cost of acquiring, constructing or improving the asset;
- Liens on the Property of our subsidiaries in our favor or in the favor of
any wholly owned Restricted Subsidiary;
- judgment or judicial attachment Liens for any judgment that is not an event
of default under the indenture;
- Liens securing any reimbursement, indemnification or similar obligation or
liability incurred in the ordinary course of business for any letter of credit,
letter of guaranty, banker's acceptance, bill of exchange or similar instrument
for our trade obligations or those of our subsidiaries;
- Liens imposed by law that are being contested in good faith and for which
we have set aside adequate reserves or, if not removed, could not be expected
to have a material adverse effect on us and our subsidiaries;
- any Lien existing as a result of a Capital Lease Obligation that is not otherwise
prohibited by the indenture; and
- the extension, renewal or replacement of any lien referred to in the foregoing clauses or this clause.
Notwithstanding the foregoing, we and any Restricted Subsidiary may create, incur or permit to exist any lien to secure Indebtedness in addition to those permitted by the preceding sentence, and renew, extend or replace such liens, provided that at the time of such creation, incurrence, renewal, extension or replacement, after giving effect thereto, the aggregate amount of all such Indebtedness of our Company and our Restricted Subsidiaries and the aggregate Attributable Debt of all Sale and Leaseback Transactions of our Company and our Restricted Subsidiaries at any one time outstanding together shall not exceed _% of Consolidated Assets. (section 1007)
12
Sale and leaseback transactions
Neither we nor any Restricted Subsidiary may enter
into any Sale and Leaseback Transaction, unless either:
- we or the Restricted Subsidiary would be entitled pursuant to the "- Lien
on assets" covenant to create Indebtedness secured by a Lien on the Property
in an amount equal to the Attributable Debt of the Sale and Leaseback Transaction
without the debt securities being equally and ratably secured; or
- we or the Restricted Subsidiary applies, in the case of a sale or transfer for cash, an amount equal to the greater of the fair market value or the net proceeds of the Sale and Leaseback and, in the case of a sale or transfer otherwise than for cash, an amount equal to the fair market value of the Property leased, to the retirement, within 180 days after the Sale and Leaseback Transaction, of the debt securities or other Indebtedness ranking on parity with the debt securities and owing to a Person other than us or any of our Affiliates or applies it to the construction or improvement of real property or personal property used in the ordinary course of business.
(section 1008)
Limitation on merger, consolidation and sale of assets
We may not consolidate with or merge into any other entity or transfer or lease substantially all of our properties and assets to any person unless:
- the successor is organized under the laws of the United States or a state
thereof;
- the successor assumes by supplemental indenture the obligations of its predecessor
(that is, all our obligations under the debt securities and the indenture);
and
- after giving effect to the transaction, there is no default under the indenture.
The surviving transferee or lessee corporation will be our successor, and we will be relieved of all obligations under the debt securities and the indenture. (sections 801 and 802)
13
Defined Terms
"Attributable Debt" means, in respect of a Sale
and Leaseback Transaction, at the time of determination, the lesser of (1) the
fair market value of the property subject to such arrangement or (2) the present
value (discounted at the rate per annum equal to the interest borne by the debt
securities on a weighted average basis) of the total obligations of the lessee
for rental payments during the remaining term of the lease included in such
arrangement after excluding all amounts required to be paid on account of maintenance
and repairs, insurance, taxes and similar charges.
"Capital Stock" of any Person means shares, interests,
rights to purchase, warrants, options, participation or other equivalents of
or interests in (however designated) equity of such Person, including any preferred
stock, but excluding any debt securities convertible into such equity.
"Capital Lease Obligations" means indebtedness
represented by obligations under a lease that is required to be capitalized
for financial reporting purposes in accordance with generally accepted accounting
principles. The amount of indebtedness will be the capitalized amount of the
obligations determined in accordance with generally accepted accounting principles
consistently applied.
"Consolidated Assets" of the Company and its subsidiaries
means the consolidated total assets of the Company and its subsidiaries as reflected
in the Company's most recent balance sheet preceding the date of determination
prepared in accordance with generally accepted accounting principles consistently
applied.
"Indebtedness" means, with respect to any Person
(without duplication):
- any liability of such Person (A) for borrowed money, or under any reimbursement
obligation relating to a letter of credit, or (B) evidenced by a bond, note,
debenture or similar instrument (including a purchase money obligation arising
in connection with the acquisition of any businesses, properties or assets
of any kind) (other than a trade payable or a current liability arising in
the ordinary course of business), or (C) for the payment of money relating
to any Capital Lease Obligations;
- any liability of others described in the preceding clause (1) that the
Person has guaranteed or that is otherwise its legal liability;
- any amendment, supplement, modification, deferral, renewal, extension or
refunding of any liability of the types referred to in clause (1) or (2) above;
and
- in the case of any Restricted Subsidiary, the aggregate preference in respect of amounts payable on the issued and outstanding shares of preferred stock of such Restricted Subsidiary in the event of any voluntary or involuntary liquidation, dissolution or winding up (excluding any such preference attributable to such shares of preferred stock that are owned by the Company or any Restricted Subsidiary).
"Lien" means any mortgage, pledge, lien, security interest, charge or other encumbrance or preferential arrangement (including any conditional sale or other title retention agreement or lease in the nature thereof other than a title retention agreement in connection with the purchase of goods in the ordinary course of business which is outstanding for not more than 90 days).
14
"Permitted Liens" means
- Liens imposed by law for taxes, fees, assessments or other governmental charges or levies that are not yet due;
- carriers', warehousemen's, mechanics', materialmen's, repairmen's, vendors' or lessors' Liens (and deposits to obtain the release of such Liens), set-off rights and other like Liens imposed by law (or contract, to the extent that such contractual Liens are similar in nature and scope to Liens imposed by law), in each case arising in the ordinary course of business and securing obligations that are not overdue by more than 60 days or are being contested in good faith;
- Liens incurred and pledges and deposits made in the ordinary course of business in connection with workers' compensation, disability or unemployment insurance, old-age pensions, retiree health benefits and other social security laws or regulations;
- deposits to secure the performance of bids, trade contracts, leases, statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature, in each case in the ordinary course of business; and
- (A) easements, covenants, conditions, restrictions, leases, subleases, licenses, rights of way, minor irregularities in, or lack of, title and similar encumbrances affecting real property, (B) with respect to any lessee's or licensee's interest in real or personal property, mortgages, liens, rights and obligations and other encumbrances arising by, through or under any owner, lessor or licensor thereof, with or without the lessee's or licensee's consent, and (C) leases, licenses, rights and obligations in connection with patents, copyrights, trademarks, trade names and other intellectual property, in each case that do not secure the payment of borrowed money (other than, with respect to any lessee's or licensee's interest in real or personal property, mortgages, liens, rights and obligations and other encumbrances arising by, through or under any owner, lessor or licensor thereof) to the extent, in the case of each of (A), (B) and (C), that the Liens referred to therein do not, in the aggregate, materially detract from the value of the affected property as used by the Company or any subsidiary in the ordinary course of business or materially interfere with the ordinary conduct of the business of the Company and its subsidiaries taken as a whole.
"Person" means any individual, firm, corporation,
partnership, association, joint venture, tribunal, limited liability company,
trust, government or political subdivision or agency or instrumentality thereof,
or any other entity or organization.
"Property" means any asset, revenue or any other
property, whether tangible or intangible, real or personal, including, without
limitation, any right to receive income.
"Restricted Subsidiary" means any subsidiary of
the Company if at the end of the most recent fiscal quarter, the total assets
of such subsidiary exceed % of consolidated total assets of the Company and
its subsidiaries, determined in accordance with generally accepted accounting
principles consistently applied.
"Sale and Leaseback Transaction" means any transaction
or series of related transactions pursuant to which the Company or any Restricted
Subsidiary sells or transfers any Property to any Person with the intention
of taking back a lease of such Property.
"Significant Subsidiary" has the meaning specified,
as of the date of the indenture, in Rule 1-02 of Regulation S-X promulgated
under the Securities Act.
15
Registration of Transfer and Exchange
All debt securities issued upon any registration
of transfer or exchange of debt securities will be valid obligations of ours,
evidencing the same debt and entitled to the same rights under the indenture
as the debt securities surrendered in the registration of transfer or exchange.
Registration of Transfer
Holders of registered debt securities may present
their securities for registration of transfer at the office of one or more security
registrars designated and maintained by us. (section 305)
We will not be required to register the transfer
of or exchange debt securities under the following conditions:
- We will not be required to register the transfer of or exchange any debt securities
during a period of 15 days before any selection of those debt securities to
be redeemed.
- We will not be required to register the transfer of or exchange any debt securities
selected for redemption, in whole or in part, except the unredeemed portion
of any debt securities being redeemed in part.
- We will not be required to register the transfer of or exchange debt securities of any holder who has exercised an option to require the repurchase of those debt securities prior to their stated maturity date, except the portion not being repurchased.
(section 305)
Exchange
At your option, you may exchange your registered
debt securities of any series (except a global security, as set forth below)
for an equal principal amount of other registered debt securities of the same
series having authorized denominations upon surrender to our designated agent.
We may at any time exchange debt securities issued
as one or more global securities for an equal principal amount of debt securities
of the same series in definitive registered form. In this case we will deliver
to the holders new debt securities in definitive registered form in the same
aggregate principal amount as the global securities being exchanged.
The depositary of the global securities may also
decide at any time to surrender one or more global securities in exchange for
debt securities of the same series in definitive registered form, in which case
we will deliver the new debt securities in definitive form to the persons specified
by the depositary, in an aggregate principal amount equal to, and in exchange
for, each person's beneficial interest in the global securities. (section 305)
Notwithstanding the above, we will not be required
to exchange any debt securities if, as a result of the exchange, we would suffer
adverse consequences under any U.S. law or regulation. (section 305)
Global Securities
If we decide to issue debt securities in the form
of one or more global securities, then we will register the global securities
in the name of the depositary for the global securities or the nominee of the
depositary and the global securities will be delivered by the trustee to the
depositary for credit to the accounts of the holders of beneficial interests
in the debt securities.
The prospectus supplement or term sheet will describe
the specific terms of the depositary arrangement for debt securities of a series
that are issued in global form. None of our Company, the trustee, any paying
agent or the security registrar will have any responsibility or liability for
any aspect of the records relating to or payments made on account of beneficial
ownership interests in a global debt security or for maintaining, supervising
or reviewing any records relating to these beneficial ownership interests.
16
Defeasance of Indenture
We can terminate all of our obligations under
the indenture with respect to the debt securities, other than the obligation
to pay interest on and the principal of the debt securities and certain other
obligations, at any time by:
- depositing money or U.S. government obligations with the trustee in an amount
sufficient to pay the principal of and interest on the debt securities to their
maturity; and
- complying with certain other conditions, including delivery to the trustee of an opinion of counsel to the effect that holders of debt securities will not recognize income, gain or loss for U.S. federal income tax purposes as a result of our defeasance.
- depositing money or U.S. government obligations with the trustee in an amount
sufficient to pay the principal of and interest on the debt securities to their
maturity, and
- complying with certain other conditions, including delivery to the trustee of an opinion of counsel stating that there has been a ruling by the Internal Revenue Service, or a change in the federal tax law since the date of the indenture, to the effect that holders of debt securities will not recognize income, gain or loss for U.S. federal income tax purposes as a result of our defeasance.
Payments of Unclaimed Moneys
Moneys deposited with the trustee or any paying agent for the payment of principal of or premium and interest on any debt security that remains unclaimed for two years will be repaid to us at our request, unless the law requires otherwise. If this happens and you want to claim these moneys, you must look to us and not to the trustee or paying agent. (section 409)
Events of Default, Notices, and Waiver
Events of default
An "event of default" regarding any series of debt securities is any one of the following events:
- default for 30 days in the payment of any interest installment when due and payable;
- default in the payment of principal or premium when due at its stated maturity,
by declaration, when called for redemption or otherwise;
- default in the performance of any covenant in the debt securities or in
the indenture by us for 60 days after notice to us by the trustee or by holders
of 25% in principal amount of the outstanding debt securities of that series;
- acceleration of debt securities of another series or any other indebtedness
of ours or one of our Significant Subsidiaries for borrowed money, in an aggregate
principal amount exceeding $_ million under the terms of the instrument or
instruments under which the indebtedness is issued or secured, if the acceleration
is not annulled within 30 days after written notice as provided in the indenture;
- a final, non-appealable judgment or order for the payment of money in excess
of $_________ million rendered against us or one of our Significant Subsidiaries
that is not paid or discharged within 60 days following entry of such judgment
or order;
- certain events of bankruptcy, insolvency and reorganization involving us;
and
- any other event of default of that series that is specified in the prospectus supplement or term sheet.
17
(section 501)
A default regarding a single series of debt securities
will not necessarily constitute a default regarding any other series.
If an event of default for any series of debt
securities occurs and is continuing (other than an event of default involving
the bankruptcy, insolvency or reorganization of our Company), either the trustee
or the holders of 25% in principal amount of the outstanding debt securities
of that series may declare the principal (or, in the case of (a) OID debt securities,
a lesser amount as provided in those OID debt securities or (b) indexed debt
securities, an amount determined by the terms of those indexed debt securities),
of all the debt securities of that series, together with any accrued interest
on the debt securities, to be immediately due and payable by notice in writing
to us. If it is the holders of debt securities who give notice of that declaration
of acceleration to us, then they must also give notice to the trustee. (section
502)
If an event of default occurs that involves the
bankruptcy, insolvency or reorganization of our Company, as set forth above,
then all unpaid principal amounts (or, if the debt securities are (a) OID debt
securities, then the portion of the principal amount that is specified in those
OID debt securities or (b) indexed debt securities, an amount determined by
the terms of those indexed debt securities) and accrued interest on all debt
securities of each series will immediately become due and payable, without any
action by the trustee or any holder of debt securities. (section 502)
In order for holders of debt securities to initiate
proceedings for a remedy under the indenture, 25% in principal amount must first
give notice to us as provided above, must request that the trustee initiate
a proceeding in its own name and must offer the trustee a reasonable indemnity
against costs and liabilities. If the trustee still refuses for 60 days to initiate
the proceeding, and no inconsistent direction has been given to the trustee
by holders of a majority of the debt securities of the same series, the holders
may initiate a proceeding as long as they do not adversely affect the rights
of any other holders of that series. (section 507)
The holders of a majority in principal amount
of the outstanding debt securities of a series may rescind a declaration of
acceleration if all events of default, besides the failure to pay principal
or interest due solely because of the declaration of acceleration, have been
cured or waived. (section 502)
If we default on the payment of any installment
of interest and fail to cure the default within 30 days, or if we default on
the payment of principal when it becomes due, then the trustee may require us
to pay all amounts due to the trustee, with interest on the overdue principal
or interest payments, in addition to the expenses of collection. (section 503)
A judgment for money damages by courts in the
United States, including a money judgment based on an obligation expressed in
a foreign currency, will ordinarily be rendered only in U.S. dollars. New York
statutory law provides that a court shall render a judgment or decree in the
foreign currency of the underlying obligation and that the judgment or decree
shall be converted into U.S. dollars at the exchange rate prevailing on the
date of entry of the judgment or decree. The indenture requires us to pay additional
amounts necessary to protect holders if a court requires a conversion to be
made on a date other than a judgment date.
Notices
The trustee is required to give notice to holders
of a series of debt securities of a default that remains uncured or has not
been waived, and that is known to the trustee, within 90 days after the default
has occurred. In the event of a default in the performance of any covenant in
the debt securities or the indenture that results under the indenture in notice
to us by the trustee after 90 days, the trustee shall not give notice to the
holders of debt securities until 60 days after the giving of notice to us. The
trustee may not withhold the notice in the case of a default in the payment
of principal of and premium or interest on any of the debt securities. (section
602)
Waiver
The holders of a majority in principal amount
of the outstanding debt securities of a series may waive any past default or
event of default except a default in the payment of principal of or premium
or interest on the debt securities of that series or a default relating to a
provision that cannot be amended without the consent of each affected holder.
(section 513)
Subordination
The terms of any series of subordinated debt securities
will be set forth in a prospectus supplement relating to the series. Our obligations
to make any payment of the principal of and premium, if any, and interest on,
any subordinated debt securities will be subordinate and junior in right of
payment to the prior payment in full of all of our senior debt, whether outstanding
on the date of the supplemental indenture relating to the subordinated debt
securities or thereafter incurred. (section 13.01)
18
Conversion
The terms on which debt securities of any series
that are convertible into or exchangeable for common stock or other securities
will be set forth in a prospectus supplement relating to the convertible series.
Those terms will include provisions relating to whether conversion or exchange
is mandatory, at the option of the holder or at our option, and may include
provisions pursuant to which the number of shares of common stock or other securities
to be received by the holders of debt securities would be subject to adjustment.
Reports
We are required to file an officer's certificate
with the trustee every year confirming that we are complying with all conditions
and covenants in the indenture. (section 1005)
We must also file with the trustee copies of our
annual reports and the information and other documents that we may be required
to file with the SEC under Section 13 or Section 15(d) of the Securities Exchange
Act of 1934, as amended. These documents must be filed with the trustee within
15 days after they are required to be filed with the SEC. If we are not required
to file the information, documents or reports under either of these Sections,
then we must file with the trustee and the SEC, in accordance with the rules
and regulations of the SEC, the supplementary and periodic information, documents
and reports that may be required by Section 13 of the Exchange Act, in respect
of a debt security listed and registered on a national securities exchange,
as may be required by the rules and regulations of the SEC.
Within 30 days of filing the information, documents
or reports referred to above with the trustee, we must mail to the holders of
the debt securities any summaries of the information, documents or reports that
are required to be sent to the holders by the rules and regulations of the SEC.
(section 704)
Rights and Duties of the Trustee
The holders of a majority in principal amount
of outstanding debt securities of any series may direct the time, method and
place of conducting any proceeding for any remedy available to the trustee or
exercising any trust or other power conferred on the trustee. The trustee may
decline to follow that direction if it would involve the trustee in personal
liability or would be illegal. (section 512) During a default, the trustee is
required to exercise the standard of care and skill that a prudent person would
exercise under the circumstances in the conduct of his or her own affairs. (section
601) The trustee is not obligated to exercise any of its rights or powers under
the indenture at the request or direction of any of the holders of debt securities
unless those holders have offered to the trustee reasonable security or indemnity.
(section 603)
The trustee is entitled, in the absence of bad
faith on its part, to rely on an officer's certificate before taking action
under the indenture. (section 603)
Supplemental Indentures
Supplemental indentures not requiring consent
of holders
Without the consent of any holders of debt securities,
we and the trustee may supplement the indenture, among other things, to:
- pledge property to the trustee as security for the debt securities;
- reflect that another entity has succeeded us and assumed our covenants
and obligations under the debt securities and the indenture;
- cure any ambiguity or inconsistency in the indenture or in the debt securities
or make any other provisions necessary or desirable, as long as the interests
of the holders of the debt securities are not adversely affected in any material
respect;
- issue and establish the form and terms of any series of debt securities
as provided in the indenture;
- add to our covenants further covenants for the benefit of the holders of
debt securities (and if the covenants are for the benefit of less than all
series of debt securities, stating which series are entitled to benefit);
- add any additional event of default (and if the new event of default applies
to fewer than all series of debt securities, stating to which series it applies);
- change the trustee or provide for an additional trustee;
- provide additional provisions for bearer debt securities so long as the
action does not adversely affect the interests of holders of any debt securities
in any material respect; or
- modify the indenture in order to continue its qualification under the Trust Indenture Act of 1939 or as may be necessary or desirable in accordance with amendments to that Act.
19
(section 901)
Supplemental indentures requiring consents of holders
With the consent of the holders of at least a
majority in principal amount of the series of the debt securities that would
be affected by a modification of the indenture, the indenture permits us and
the trustee to supplement the indenture or modify in any way the terms of the
indenture or the rights of the holders of the debt securities. However, without
the consent of each holder of all of the debt securities affected by that modification,
we and the trustee may not:
- reduce the principal of or premium on or change the stated final maturity
of any debt security;
- reduce the rate of or change the time for payment of interest on any debt
security (or, in the case of OID debt securities, reduce the rate of accretion
of the OID);
- change any of our obligations to pay additional amounts under the indenture;
- reduce or alter the method of computation of any amount payable upon redemption,
repayment or purchase of any debt security by us (or the time when the redemption,
repayment or purchase may be made);
- make the principal or interest on any debt security payable in a currency
other than that stated in the debt security or change the place of payment;
- reduce the amount of principal due on an OID debt security upon acceleration
of maturity or provable in bankruptcy or reduce the amount payable under the
terms of an indexed debt security upon acceleration of maturity or provable
in bankruptcy;
- impair any right of repayment or purchase at the option of any holder of
debt securities;
- modify the right of any holder of debt securities to receive or sue for
payment of the principal or interest on a debt security that would be due
and payable at the maturity thereof or upon redemption; or
- reduce the principal amount of the outstanding debt securities of any series required to supplement the indenture or to waive any of its provisions.
A supplemental indenture that modifies or eliminates a provision intended to benefit the holders of one series of debt securities will not affect the rights under the indenture of holders of other series of debt securities.
Redemption
The specific terms of any redemption of a series of debt securities will be contained in the prospectus supplement or term sheet for that series. Generally, we must send notice of redemption to the holders at least 30 days but not more than 60 days prior to the redemption date. The notice will specify:
- the principal amount being redeemed;
- the redemption date;
- the redemption price;
- the place or places of payment;
- the CUSIP number of the debt securities being redeemed;
- whether the redemption is pursuant to a sinking fund;
- that on the redemption date, interest (or, in the case of OID debt securities,
original issue discount) will cease to accrue; and
- if bearer debt securities are being redeemed, that those bearer debt securities must be accompanied by all coupons maturing after the redemption date or the amount of the missing coupons will be deducted from the redemption price, or indemnity must be furnished, and whether those bearer debt securities may be exchanged for registered debt securities not being redeemed.
20
(section 1104)
On or before any redemption date, we will deposit an amount of money with the
trustee or with a paying agent sufficient to pay the redemption price. (section
1105)
If less than all the debt securities are being redeemed, the trustee shall select
the debt securities to be redeemed using a method it considers fair. (section
1103) After the redemption date, holders of debt securities that were redeemed
will have no rights with respect to the debt securities except the right to
receive the redemption price and any unpaid interest to the redemption date.
(section 1106)
Governing Law
The laws of the State of New York govern the indenture and will govern the debt
securities. (section 112)
DESCRIPTION OF COMMON STOCK
Our authorized common stock consists of 30 million
shares, $0.025 par value per share. At October 31, 2002, there were 17,874,510
shares of common stock issued and outstanding. The approximate number of shareholders
of record of our common stock as of October 31, 2002 was 225.
Each share of our common stock is entitled to
one vote on all matters requiring a vote of shareholders and, subject to the
rights of the holders of any outstanding shares of preferred stock, are entitled
to receive any dividends, in cash, securities or property, as our board may
declare.
In the event of our liquidation, dissolution or
winding up, either voluntary or involuntary, subject to the rights of the holders
of any outstanding shares of preferred stock, holders of common stock are entitled
to share pro-rata in all of our remaining assets available for distribution.
The common stock issued by this prospectus will,
when issued, be fully paid and nonassessable and will not have, or be subject
to, any preemptive or similar rights.
American Stock Transfer & Trust Company, 59
Maiden Lane, New York, N.Y. 10038 is the transfer agent and registrar for our
common stock. Its phone number is (212) 936-5100.
21
DESCRIPTION OF PREFERRED STOCK
Our board of directors is authorized, without further vote or action by the
holders of our common stock, to issue by resolution an aggregate of 2 million
shares of preferred stock. These shares of preferred stock may be issued in
one or more series as established from time to time by our board of directors.
Our board also is authorized to fix the number of shares and the designation
or title of each series of preferred stock prior to the issuance of any shares
of that series. Regarding each class or series of preferred stock, our board
will fix the voting powers which may be full or limited, or there may be no
voting powers. Our board will also determine the preferences and relative, participating,
optional or other special rights and qualifications, limitations or restrictions,
of each series of preferred stock. Our board is further authorized to increase
or decrease the number of shares of any series subsequent to the issuance of
shares of that series, but not below the number of shares of the class or series
then outstanding. Terms authorized by the board with respect to preferred stock,
including convertible preferred stock, will be disclosed in the prospectus supplement
relating to preferred stock.
No shares of preferred stock are presently outstanding and we have no plans
to issue a new series of preferred stock. It is not possible to state the effect
of the authorization and issuance of any series of preferred stock upon the
rights of the holders of common stock until our board of directors determines
the specific terms, rights and preferences of a series of preferred stock. However,
possible effects might include restricting dividends on the common stock, diluting
the voting power of the common stock or impairing the liquidation rights of
the common stock without further action by holders of common stock. In addition,
under some circumstances, the issuance of preferred stock may render more difficult
or tend to discourage a merger, tender offer or proxy contest, the assumption
of control by a holder of a large block of our securities or the removal of
incumbent management, which could thereby depress the market price of our common
stock.
DESCRIPTION OF WARRANTS
We have described below the general terms and provisions of the debt warrants and equity warrants to which a prospectus supplement may relate. We will describe the particular terms of any debt warrants and equity warrants offered by any prospectus supplement in the prospectus supplement relating to such debt warrants or equity warrants.
22
We may issue debt warrants and equity warrants, evidenced by warrant certificates under a warrant agreement, independently or together with any debt securities, preferred stock or common stock. The warrants may be transferable with or separate from such securities. If we offer debt warrants, the applicable prospectus supplement will describe the terms of the debt warrants, including the following: (i) the offering price, if any, including the currency, or currency unit in which such price will be payable; (ii) the designation, aggregate principal amount and terms of the offered debt securities with which the debt warrants are issued and the number of debt warrants issued with each such offered debt security; (iii) if applicable, the date on or after which the debt warrants and the related offered debt securities will be separately transferable; (iv) the designation, aggregate principal amount and terms of debt securities purchasable upon exercise of one debt warrant and the price or prices at which, and the currency, or currency unit in which such principal amount of debt securities may be purchased upon exercise; (v) the date on which the right to exercise the debt warrants commences and the date on which such right expires; (vi) any U.S. Federal income tax consequences; (vii) whether the debt warrants represented by the warrant certificates will be issued in registered or bearer form or both; and (viii) any other material terms of the debt warrants. If we offer equity warrants, the applicable prospectus supplement will describe the terms of the equity warrants, including the following: (i) the offering price, if any, including the currency or currency unit in which such price will be payable; (ii) the designation of any series of preferred stock purchasable upon exercise of the equity warrants; (iii) the number of shares of preferred stock or common stock purchasable upon exercise of one equity warrant, and the price or prices at which, and the currency, or currency unit in which such shares may be purchased upon exercise; (iv) the date on which the right to exercise the equity warrants and the date on which such right expires; (v) any U.S. Federal income tax consequences; (vi) whether the equity warrants represented by the warrant certificate will be issued in registered or bearer form or both; (vii) whether the equity warrants or the underlying preferred stock or common stock will be listed on any national securities exchange; and (viii) any other material terms of the equity warrants. In addition, if we sell any debt warrants or equity warrants for any foreign currency or currency units, the restrictions, elections, tax consequences, specific terms and other information with respect to such issue will be specified in the applicable prospectus supplement.
Warrant certificates, if any, may be exchanged for new warrant certificates of different denominations and may (if in registered form) be presented for registration of transfer at the corporate trust office of the warrant agent, which will be listed in the applicable prospectus supplement, or at such other office as may be set forth therein. Warrantholders do not have any of the rights of holders of debt securities (except to the extent that the consent of warrantholders may be required for certain modifications of the terms of the indenture under which the series of offered debt securities issuable upon exercise of the warrants to be issued) or preferred or common stockholders and are not entitled to payments of principal and interest, if any, on debt securities or to dividends or other distributions made with respect to preferred stock or common stock.
Warrants may be exercised by surrendering the warrant certificate, if any, at the corporate trust office or other designated office of the warrant agent, with (i) the form of election to purchase on the reverse side of the warrant certificate, if any, properly completed and executed, and (ii) payment in full of the exercise price, as set forth in the applicable prospectus supplement. Upon exercise of warrants, the warrant agent will, as soon as practicable, deliver the debt securities, preferred stock or common stock issuable upon the exercise of the warrants in authorized denominations in accordance with the instructions of the exercise warrantholder and at the sole cost and risk of such holder. If less than all of the warrants evidenced by the warrant certificate are exercised, a new warrant certificate will be issued for the remaining amount of unexercised warrants, if sufficient time exists prior to the expiration date.
23
PLAN OF DISTRIBUTION
GeneralAny of the securities offered hereby may be sold in any one or more of the following ways from time to time:
- to or through underwriters;
- through dealers;
- directly to other purchasers; or
- through agents.
The distribution of the securities may be effected
from time to time in one or more transactions at a fixed price or prices, which
may be changed, or at market prices prevailing at the time of sale, at prices
related to such prevailing market prices or at negotiated prices.
In connection with the sale of securities, underwriters
may receive compensation from us or purchasers of securities for whom they may
act as agents, in the form of discounts, concessions or commissions. Underwriters,
dealers and agents that participate in the distribution of securities may be
deemed to be underwriters, and any discounts or commissions received by them
from us and any profit on the resale of securities by them may be deemed to
be underwriting discounts and commissions under the Securities Act. Any person
who may be deemed to be an underwriter will be identified, and the compensation
received from us will be described, in the prospectus supplement.
During and after an offering through underwriters,
the underwriters may purchase and sell the securities in the open market. These
transactions may include overallotment and stabilizing transactions and purchases
to cover syndicate short positions created in connection with the offering.
The underwriters may also impose a penalty bid, whereby selling concessions
allowed to syndicate members or other broker-dealers for the securities sold
for their account may be reclaimed by the syndicate if those securities are
repurchased by the syndicate in stabilizing or covering transactions. These
activities may stabilize, maintain or otherwise affect the market price of the
securities, which may be higher than the price that might otherwise prevail
in the open market, and, if commenced, may be discontinued at any time.
Except for our common stock, all securities, when
first issued, will have no established trading market. Any underwriters or agents
to or through whom securities are sold by us for public offering and sale may
make a market in those securities, but the underwriters or agents will not be
obligated to do so and may discontinue any market making at any time without
notice. We cannot assure you as to the liquidity of the trading market for any
of our securities.
Under agreements which we may enter into, underwriters,
dealers and agents who participate in the distribution of securities may be
entitled to indemnification by us against or contribution toward certain liabilities,
including liabilities under the Securities Act.
24
LEGAL MATTERS
The validity of the issuance of the securities offered in this offering will be passed upon for us by Milbank, Tweed, Hadley & McCloy LLP.
EXPERTS
The financial statements incorporated in this prospectus by reference to the annual report on Form 10-K, as amended, for the year ended December 31, 2001 have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, independent accountants, given on the authority of said firm as experts in auditing and accounting.
WHERE YOU CAN FIND MORE INFORMATION
Available InformationWe have filed with the SEC a registration statement on Form S-3 to register the securities offered by this prospectus. However, this prospectus does not contain all of the information contained in the registration statement and the exhibits and schedules to the registration statement. We strongly encourage you to carefully read the registration statement and the exhibits and schedules to the registration statement. We also file annual, quarterly and special reports, proxy statements and other information with the SEC.
You may inspect and copy these materials at the public reference facilities maintained by the SEC at 450 Fifth Street, N.W., Washington, D.C. 20549. You may also obtain copies of these materials from the SEC at prescribed rates by writing to the SEC's Public Reference Section, 450 Fifth Street, N.W., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference rooms. Our SEC filings are also available to the public from the SEC's website at www.sec.gov. Our common stock is quoted on the Nasdaq National Market under the symbol "NRGN". You may inspect reports and other information concerning us at the offices of the National Association of Securities Dealers, Inc., 1735 K Street, N.W., Washington, D.C. 20006.
Incorporation of Certain Documents by Reference
The SEC allows us to "incorporate by reference" the information contained in documents that we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference which we filed with the SEC prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede this information. We incorporate by reference the documents listed below and any future filings we will make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934:
- Our Annual Report on Form 10-K for the fiscal year ended December 31, 2001
and the amendments thereto filed on April 30, 2002, October 31, 2002, January
9, 2003 and January 21, 2003, including all material incorporated by reference
therein; and
- Our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2002, June 30, 2002 and September 30, 2002 including, in each case, all material incorporated by reference therein; and
- Our Current Reports on Form 8-K filed on January 11, 2002, October 9, 2002 and November 13, 2002.
If you request, by written or oral request, a copy of any or all of the documents incorporated by reference, we will send you the requested copies at no charge. We will not, however, send you the exhibits to such documents unless such exhibits are specifically incorporated by reference in such documents. You should direct requests for such copies to Elaine Beckwith, Associate Director of Investor and Public Relations, of Neurogen, at 35 Northeast Industrial Road, Branford, Connecticut 06504, (203) 488-8201.
25